Xilio Therapeutics IncXLO
Price$9.05Intrinsic value$9.839% above price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $43.8M+590.4% YoYTTM through 31 Dec 2025
Net Income -$35MTTM through 31 Dec 2025
Free Cash Flow -$5.5MTTM through 31 Dec 2025

Margins

Current
Gross Margin96.5%
Operating Margin-95.9%
Net Margin-80.1%

Returns

-99.3%ROE
-22.7%ROA

Balance Sheet Health

Debt / Equity0.20x
Current Ratio2.58x
Net Debt-$130.6Mnet cash position
Cash & Equivalents$137.5M

Quality Metrics

FCF Margin-12.6%
Earnings-Beat Rate0.0%

Dividend

No dividend
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.